Approvals: Novartis’ Silver Lining

Gopal,Kevin;

Article

Pharmaceutical Executive

October 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-10-01-2001

Volume0

Issue 0

Approvals: Novartis’ Silver Lining

Author(s):

Kevin Gopal

Basel-A series of product approvals in recent weeks could go some way to compensate for setbacks in Novartis’ pipeline. The approvals came as the Swiss company reported healthy half-year figures and an 11 percent sales increase.

Articles in this issue

National Crisis Supercedes Coverage Debate

PBMs: Merck-Medco in the Hot Seat

National Crisis Supercedes Coverage Debate

A Five-Year Forecast: Clear Seas Ahead?

Weak Bones, Strong Market

Approvals: Novartis’ Silver Lining

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Approvals: Novartis’ Silver Lining

Newsletter